Retrieved from Gimunov, M., Bozdch, M., Novk, J., et al
Whether semaglutide acts in a similar way is still unclear
It mimics a hormone which slows the release of insulin, but also extends the feeling of being full
Researchers analysed six years of data from more than 16,800 neuro-opthalmology patients and found that the risk of NAION occurring for the first time over a 36-month time period was 8.9% among patients with T2DM who had been prescribed semaglutide (n=194), compared with 1.8% in 516 patients with T2DM prescribed other antidiabetic medicines
Iran War Europe Wildfires World Politics Entertainment HealthWatch MoneyWatch Crime Space Sports Brand Studio The Free Press Local News Atlanta Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News 24/7 Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas 48 Hours 60 Minutes Shows 48 Hours 60 Minutes CBS Evening News CBS Mornings CBS Morning News CBS Reports CBS Saturday Morning The Daily Report The Dish Face the Nation Sunday Morning The Takeout Things That Matter The Uplift CBS News Investigates CBS News Confirmed Podcasts Newsletters Download Our App CBS News Team Executive Team Brand Studio Paramount+ Join Our Talent Community RSS Feeds Watch CBS News How the rise of GLP-1 drugs is shifting consumer habits The rise in the use of GLP-1 weight-loss drugs across the U.S
